Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective. - Tarantino P; Sammons S; Gadi VK; Pathak P; Sopher G; Delea T; Stellato D (Journal of medical economics, 2025)